There are several reasons for this volatility.Management takes steps to keep shareholders
informed through the Company Website, Bloomberg, Pink Sheets and Business Wire. These
public announcements are meant to keep shareholders as informed as possible within the
limitations of the disclosure agreements between MDEChem and EnviroFuels LLC.
As of this date, MDECHEM has a minority ownership interest (50,000 Units) and a 10%
interest in net profits of EnviroFuels, LLC.
EnviroFuels has raised significant new funding to develop the technology purchased from
MDEChem, Inc. This technology provides for improvements in fuel economy and reduction of
emissions in internal combustion engines. EnviroFuels has made significant inroads into the
railroad, mining, marine, power generation and construction industries, and is acquiring new
multinational customers on a continuing basis.
Shareholders should be aware that the world wide usage of hydrocarbon fuels for combustion
is over 2 trillion dollars annually, EnviroFuels DFC product underwent an extensive EPA/ETV
testing under a protocol designed by The Greenhouse Gas Technology Institute. This testing
validated the fuel savings and environmental benefits claimed by EnviroFuels, LLC.
Find results at http://www.epa.gov/etv and on www.envirofuelsllp.com.
MDEChem is not aware of any EPA tested product that approaches the fuel economy and
emissions reductions achieved by EnviroFuels DFC. Further, the EU and the State of
California have announced new initiatives to achieve emission reduction targets within
the next several years. EnviroFuels has the only product that can almost immediately
achieve the regulatory objectives. At the same time, ongoing tests with major multinational
users of diesel fuels are reporting significant reductions in maintenance costs. These
results augur well for the continuing success of EnviroFuels
MDEChem incorporated MaxHeal, Inc. in August 2006. MaxHeal, Inc. is in the process of
marketing "MaxHeal™ Skin Restoration Gel" to the U.S. market. This Gel is a result of
technology developed by MDEChem and is the first in a line of products to be introduced to
the U.S. market that were developed by our affiliate in Costa Rica, MED Quimica S.A.
We suggest that shareholders take a long-term view of the intrinsic value of the company’s
assets and avoid too much attention to the day traders and short sellers. Our assets and
developed drug products will have a profound effect on energy usage and on improvement in
human and animal health.
MDEChem, Inc. Information for Pink Sheets Rule 15C2-11
Dated: September 30, 2009 Issuer: MDEChem, Inc.
Office: 1000 C Street, Floresville, Texas 78114
Phone: 830.393.5293
URL: MDEChem.Com
email: corporateoffice@mdechem.com
Investor Relations: None
State and Date of Incorporation: Texas Charter # 01287912 04/08/1996
Class of security: Common Stock CUSIP: 582826301 Symbol: MDKM
Value: No Par Value
Date of report: September 30, 2009
Authorized shares: 100,000,000
Issued Shares: 20,655,243
Shares in float: 12,905,616
Shareholders: Estimated 352
List of other securities: 50,000 EnviroFuels, LLC Units
Transfer Agent: Olde Monmouth Stock Transfer, 200 Memorial Parkway, Atlantic
Highlands, NJ 07716 Phone: 732.872.272
Business Development
MDEChem, Inc. develops and commercializes products based on its
proprietary technology. The company's development work had its
inception in the efforts to form a new surface on internal parts of a
combustion engine; utilizing a "Catalyzer" developed through proprietary
technology.
U.S. Patent #5,540,788"Method of Preparing Iron-Phosphate
Conversion Surfaces", was issued in July 1996, to co-inventors Frank
Defalco and Charles R. McCoy, who incorporated MDEChem, Inc., in
the State of Texas that same year. Patent coverage in all industrial
nations was applied for under the (PTO) Patent Treaty Organization.
This patent and the PTO coverage were subsequently assigned to
MDEChem, Inc. in 1996.
In summary, the applications of MDEChem's technology produces
fuel and mechanical efficiency, less friction, less fuel use and provides
a substantial reduction in emissions.
On December 10, 2002 MDEChem, Inc completed an Asset Purchase Agreement with
Envirofuels L.P. In this sale Envirofuels purchased the intellectual property rights of
MDEChem, Inc (except for the excluded fields detailed below). The rights to these
excluded fields have been licensed back to MDEChem with an Exclusive License
Agreement on a perpetual royalty free basic.
The "excluded fields of use" are: (1) medicines to be used in treatments of humans
and animals; (2) treatments to be applied to agricultural uses including planting, growth,
harvesting and processing of crops; (3) treatments to human and animal foods; (
4) treatments applied to trees and plants; (5) treatments applied to products from
trees and plants; and (6) treatments for fire retarding and/or proofing for wood, wood
products and clothing
MDEChem is focusing its energy on the development of product
used in the treatment of humans. The key to our long-range
success will be the funding and further establishment of
MaxHeal, Inc.
Form of organization: Corporation, Incorporated in: 1996
End of Fiscal Year: December 31
No Bankruptcy, receivership or the like: No
Asset sale in 2002 described above. In addition The Agreement of
Limited Partnership of Envirofuels, L.P. dated December 10, 2002
provides that Envirofuels L.P. during the initial seven (7) year term
of the Limited Partnership will pay MDEChem a technology fee in the
amount of ten percent (10%) of the monthly net income of the
Envirofuels. MDEChem currently owns 50,000 Units of EnviroFuels LP.
In January 2000 the common stock was split 3 for 1
Delisted from OTC Bulletin Board
Business of Issuer SIC 2834
MDEChem is focusing its energy on the development of product
used in the treatment of humans. The key to our long-range
success will be the funding and further establishment of MaxHeal,
Inc.The sanitary registration of MaxHeal product in Costa Rica was
obtained on the 12th of October 1999.
The MaxHeal product was authenticated an innovative product for
skin treatment in 1999. Since then has established the
complete safety of the product. The excellent record of safety
of use on humans and the extremely favorable LD50 of the
basic solution >20% better toxicity than substances considered by the EPA as safe.
Paul W. Sack was elected as President and CEO in 2004
Increase in equity Yes
MaxHeal developed a family of hydrogels that according to a bio- availability study
done in animals in early 2001 would function in a friendly way and in a much more
efficaciously way than a solution.
The gels could be employed additionally as controlled delivery system.
A sanitary registration was filed in Costa Rica for the skin treatment gel
developed and it was approved on April 24th 2001. The registration of MaxHeal gel
as an OTC product with a designation as GRAS (Generally Regarded As Safe).
This will allow MaxHeal gel to be marketed without a prescription in the U.S. after
May of 2005.
Investment Policies
The issuer does not own or have investments in real estate.
Investments to date have been in MaxHeal for research and development.
Nature of Products
The mission of MaxHeal is to develop innovative drug formulation
based on a patented energetically charged solution, which is
owned by MDEChem.
Products: MaxHeal™ Skin Restoration Gel Distribution: United States and Central America.
Future distribution: European, Australian, Africa and the remainder of North
America
Competition: The technology of MDEChem's energetically charged basic solution and the
aspects of the body electric gives our products a unique competitive position.
Issuer's facilities. The issuer currently does not own or rent manufacturing facilities.
Production is and will be for the foreseeable future contracted with established
packaging companies.
Corporate Officers
Paul W. Sack President and CEO
and Director Re-Elected 05/18/2009
MDEChem, Inc. Principal 2004 - 2009
Shares of MDEChem: 463,264
Directors-
Fred Fischer, Director Re-Elected 05/18/2009
One year term
Occupation Integrated Resources, consultant
Shares of MDEChem: 490,000
Shannon McCoy Director Re-Elected 05/18/2009
One year term
Occupation Sales Manager, Otsuka
America Pharmaceutical Inc.
Shares of MDEChem 300,000
General Partners: No General Partners
Bank: Northern Trust Bank
Promoters: No Promoters
Control Persons: No Control Persons
Legal Council: Holland & Knight
Accountant: Stacie Albert, outside accountant
Public Relations: No Public Relations Consultants
Advisors: No other advisors
-
-
-
Tradability Opinon Letter issued by Counsel, Martin Nathan,
661 Bering Drive, Houston Texas 77057
The current directors of MDEChem, Inc. are not insured. The shareholders in a meeting held in Houston, TX on May 14th, 2004, representing 68% of the outstanding stock, voted unanimously to pass a motion to indemnify the current directors with the assets of the company.
